Nemaura Medical announced SFDA approval of sugarBEAT, its non-invasive wearable glucose sensor. The news comes following over a year of liaisons with the SFDA through TPMENA, the Company’s licensee in the Middle East, and is seen as a major breakthrough in product commercialisation in the largest territory in the Middle East, and a region with one of the world’s highest diabetes prevalence rates. Nemaura Medical is in advanced discussions to play a role in the region with its superior sensor technology, and diabetes and metabolic health management programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical Announces SFDA Approval of sugarBEAT®
- Nemaura Medical reports Q1 EPS (9c) vs. (16c) last year
- Nemaura Medical Secures $6.5m in Non-Dilutive Funding
- Nemaura Medical reports 2023 EPS (57c), consensus (53c)
- Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023
